GLAUKOS CORP.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 907

Market Cap: $7.4B

Website: http://www.glaukos.com

Clinical Trials

Performance of the Travoprost Intraocular Implant

Phase 2

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Travoprost Intracameral Implant exchanged at Month 12
Drug: Travoprost Intracameral Implant exchanged at Month 3
Drug: Travoprost Intracameral Implant exchanged at Month 6
Drug: Travoprost Intracameral Implant exchanged at Month 24
Drug: Travoprost intracameral implant exchanged at Month 21
Drug: Travoprost intracameral implant exchanged at Month 18
Drug: Travoprost intracameral implant exchanged at Month 15

First Posted Date: 2024-09-03

Last Posted Date: 2024-10-15

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 210

Registration Number: NCT06582732

Locations: 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Phase 2

Recruiting

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: Timolol maleate ophthalmic solution, 0.5%
Drug: Travoprost Ophthalmic Topical Cream mid-dose
Drug: Travoprost Ophthalmic Topical Cream high-dose
Drug: Travoprost Ophthalmic Topical Cream low-dose
Drug: Travoprost Ophthalmic Solution, 0.004%

First Posted Date: 2023-12-01

Last Posted Date: 2023-12-06

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 250

Registration Number: NCT06152861

Locations: 🇺🇸
Glaukos Clinical Study Site, Newport Beach, California, United States

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

Phase 3

Recruiting

Conditions: Glaucoma, Open-Angle

Interventions: Other: Sham procedure
Drug: Travoprost Intraocular Implant
Device: iStent infinite

First Posted Date: 2023-10-04

Last Posted Date: 2023-10-04

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 150

Registration Number: NCT06066645

Locations: 🇺🇸
Glaukos Clinical Study Site, Colorado Springs, Colorado, United States

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Phase 3

Active, not recruiting

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: iDose TR

First Posted Date: 2023-09-29

Last Posted Date: 2024-06-03

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 60

Registration Number: NCT06061718

Locations: 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Not Applicable

Recruiting

Conditions: Glaucoma

Interventions: Device: iStent Infinite

First Posted Date: 2023-09-28

Last Posted Date: 2023-09-28

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 245

Registration Number: NCT06057051

Locations: 🇺🇸
Glaukos Investigator Site, Cincinnati, Ohio, United States

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Phase 1

Recruiting

Conditions: Progressive Keratoconus

Interventions: Combination Product: NXL Energy 3
Combination Product: NXL Energy 1
Combination Product: NXL Energy 2
Combination Product: Sham Treatment

First Posted Date: 2022-04-06

Last Posted Date: 2024-07-08

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 150

Registration Number: NCT05314738

Locations: 🇺🇸
Glaukos Investigative Site, Westerville, Ohio, United States

Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor

Not Applicable

Active, not recruiting

Conditions: Glaucoma
Glaucoma, Open-Angle

Interventions: Device: iStent Infinite
Device: Competitor Device

First Posted Date: 2021-11-19

Last Posted Date: 2024-08-15

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 179

Registration Number: NCT05127551

Locations: 🇨🇦
Glaukos Investigator Sites, Montréal, Qubec, Canada

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: Pilocarpine Ophthalmic Topical Cream, Dose 2
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 3
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1
Drug: Placebo Ophthalmic Topical Cream

First Posted Date: 2021-11-17

Last Posted Date: 2023-09-01

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 123

Registration Number: NCT05124275

Locations: 🇺🇸
Glaukos Investigator, San Antonio, Texas, United States

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Phase 2

Completed

Conditions: Kerato Conjunctivitis Sicca
Dry Eye Disease

Interventions: Drug: Placebo Ophthalmic Topical Cream
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 2
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 3

First Posted Date: 2021-11-15

Last Posted Date: 2023-07-12

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 226

Registration Number: NCT05119920

Locations: 🇺🇸
Glaukos Investigator, Lynchburg, Virginia, United States

iStent Inject New Enrollment Post-Approval Study

Not Applicable

Active, not recruiting

Conditions: Glaucoma
Glaucoma, Open-Angle

Interventions: Device: iStent Inject Implantation

First Posted Date: 2020-11-12

Last Posted Date: 2024-02-23

Lead Sponsor: Glaukos Corporation

Target Recruit Count: 358

Registration Number: NCT04624698

Locations: 🇺🇸
Eye Doctors of Arizona, PLLC, Phoenix, Arizona, United States
🇺🇸
Wolstan and Goldberg Eye Associates, Torrance, California, United States
🇺🇸
Glaucoma Associates of Texas, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy